Ramipril-Teva tablets are prescribed for the following indications:
Active substance: ramipril;
1 tablet contains 2.5 mg, 5 mg or 10 mg ramipril;
Excipients: lactose, corn starch, sodium croscarmellose, sodium bicarbonate, sodium stearyl fumarate; 2.5 mg tablets - yellow iron oxide (E172) 5 mg tablets - red iron oxide (E172), yellow iron oxide (E 172).
Hypersensitivity to the active substance or to any of the excipients that make up the preparation, or other ACE inhibitors.
A history of angioedema (hereditary, idiopathic, or previously transferred with the use of ACE inhibitors or angiotensin II receptor antagonists).
Significant bilateral renal artery stenosis or renal artery stenosis in the presence of a single kidney.
Pregnant women and women who are planning to become pregnant.
Arterial hypotension or hemodynamically unstable conditions.
The simultaneous use of Ramipril-Teva with preparations containing aliskiren is contraindicated in patients with diabetes mellitus or renal dysfunction (GFR less than 60 ml / min / 1.73 m 2).
Simultaneous use with sacubitril / valsartan. Treatment with ramipril-Teva can only be started 36 hours after the last dose of sacubitril / valsartan.
It is necessary to avoid the simultaneous use of ACE inhibitors and extracorporeal treatments that lead to blood contact with negatively charged surfaces.
The preparation is for oral administration.
Ramipril-Teva is recommended to be taken at the same time every day. The preparation can be taken before, during and after meals, since food does not affect the bioavailability of the preparation. Ramipril-Teva tablets should be swallowed whole with water. They cannot be chewed or crushed.
If it is not possible to use the prescribed dose, ramipril should be used in the appropriate dosage.
Pregnant
Contraindicated.
Children
Not recommended for use.
Drivers
Carefully.
Symptoms associated with an overdose of the preparation may be: excessive peripheral vasodilation (with severe arterial hypotension, shock), bradycardia, electrolyte imbalance and renal failure. The patient's condition should be carefully monitored and symptomatic and supportive therapy should be carried out. The proposed therapeutic measures include primary detoxification (gastric lavage, administration of adsorbents), as well as measures aimed at restoring stable hemodynamics, including the administration of alpha-1 adrenergic receptor agonists or angiotensin II (angiotensinamide). Ramiprilat, the active metabolite of ramipril, is poorly excreted from the systemic circulation by hemodialysis.
The safety profile of Ramipril-Teva contains data on persistent cough and reactions caused by arterial hypotension. Serious adverse reactions include angioedema, hyperkalemia, impaired liver or kidney function, pancreatitis, severe skin reactions, and neutropenia / agranulocytosis.
The simultaneous use of Ramipril-Teva with preparations containing aliskiren is contraindicated, it is contraindicated in patients with diabetes mellitus or renal dysfunction (GFR less than 60 ml / min / 1.73 m 2).
Simultaneous use with sacubitril / valsartan is contraindicated. Treatment with ramipril-Teva can only be started 36 hours after the last dose of sacubitril / valsartan.
It is necessary to avoid the simultaneous use of ACE inhibitors and extracorporeal treatments that lead to blood contact with negatively charged surfaces.
Store at a temperature not exceeding 25 ° C out of the reach of children.
Store in original packaging to protect from moisture.
Shelf life is 2 years.
There are no reviews for this product.